# Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

> **NCT01411410** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 55 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Copanlisib (BAY80-6946)

## Key facts

- **NCT ID:** NCT01411410
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-24
- **Primary completion:** 2014-10-22
- **Final completion:** 2015-06-29
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2017-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01411410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01411410, "Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01411410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*